Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Trending on CancerNetwork

Fitting Radioligands Into the Metastatic Prostate Cancer Treatment Paradigm

Twice-Daily Chemoradiotherapy Boosts Survival in Limited-Stage SCLC

Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma